Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04545957 · ClinicalTrials.gov registry record · NA

Jump: MR Simulation For Radiation Therapy Master Protocol

A NA study of Prostate Cancer and Head and Neck Cancer, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
NA
Development phase
86
Enrollment target
2
Study locations

NCT04545957 is a NA study of Prostate Cancer and Head and Neck Cancer that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 86 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04545957, a NA study of Prostate Cancer and Head and Neck Cancer, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
NA
Development phase
86 participants
Enrollment target
2
Study locations

Study Summary

This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.

Interventions

  • RADIATION Radiation Therapy
  • DEVICE MRI Simulator

Study Locations (2)

Massachusetts

  • Brigham and Women Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2020-10-14
Est. Completion 2030-10-22
Phase NA

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT04545957

The ClinicalTrials.gov registry entry for NCT04545957 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.

NCT04545957 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04545957 about?

NCT04545957 is a clinical study titled "Jump: MR Simulation For Radiation Therapy Master Protocol". This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.

What is the current status of trial NCT04545957?

This trial is currently recruiting. It is a NA study. The enrollment target is 86 participants. The study started on 2020-10-14. Estimated completion is 2030-10-22.

What conditions does trial NCT04545957 study?

This clinical trial studies the following conditions: Prostate Cancer, Head and Neck Cancer, Liver Cancer, Recurrent Adenocarcinoma.

What interventions are being tested in trial NCT04545957?

The interventions under investigation include: Radiation Therapy (RADIATION), MRI Simulator (DEVICE).

Who is sponsoring clinical trial NCT04545957?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04545957 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.